CA2253342A1 - Biphenylsulfonamide matrix metalloproteinase inhibitors - Google Patents

Biphenylsulfonamide matrix metalloproteinase inhibitors Download PDF

Info

Publication number
CA2253342A1
CA2253342A1 CA002253342A CA2253342A CA2253342A1 CA 2253342 A1 CA2253342 A1 CA 2253342A1 CA 002253342 A CA002253342 A CA 002253342A CA 2253342 A CA2253342 A CA 2253342A CA 2253342 A1 CA2253342 A1 CA 2253342A1
Authority
CA
Canada
Prior art keywords
biphenyl
sulfonylamino
methyl
butyric acid
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002253342A
Other languages
English (en)
French (fr)
Inventor
Patrick Michael O'brien
Drago Robert Sliskovic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2253342A1 publication Critical patent/CA2253342A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/39Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/42Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
CA002253342A 1996-05-17 1997-04-24 Biphenylsulfonamide matrix metalloproteinase inhibitors Abandoned CA2253342A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1746096P 1996-05-17 1996-05-17
US60/017,460 1996-05-17
PCT/US1997/006801 WO1997044315A1 (en) 1996-05-17 1997-04-24 Biphenylsulfonamide matrix metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
CA2253342A1 true CA2253342A1 (en) 1997-11-27

Family

ID=21782716

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002253342A Abandoned CA2253342A1 (en) 1996-05-17 1997-04-24 Biphenylsulfonamide matrix metalloproteinase inhibitors

Country Status (22)

Country Link
EP (1) EP0901466B1 (cg-RX-API-DMAC10.html)
JP (1) JP2000511175A (cg-RX-API-DMAC10.html)
KR (1) KR20000011095A (cg-RX-API-DMAC10.html)
CN (1) CN1077885C (cg-RX-API-DMAC10.html)
AT (1) ATE207891T1 (cg-RX-API-DMAC10.html)
BG (1) BG63940B1 (cg-RX-API-DMAC10.html)
BR (1) BR9710841A (cg-RX-API-DMAC10.html)
CA (1) CA2253342A1 (cg-RX-API-DMAC10.html)
CZ (1) CZ294063B6 (cg-RX-API-DMAC10.html)
DE (1) DE69707865T2 (cg-RX-API-DMAC10.html)
DK (1) DK0901466T3 (cg-RX-API-DMAC10.html)
EA (1) EA001561B1 (cg-RX-API-DMAC10.html)
EE (1) EE03965B1 (cg-RX-API-DMAC10.html)
ES (1) ES2167733T3 (cg-RX-API-DMAC10.html)
IL (1) IL126832A0 (cg-RX-API-DMAC10.html)
NO (1) NO312510B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ332711A (cg-RX-API-DMAC10.html)
PL (1) PL186416B1 (cg-RX-API-DMAC10.html)
PT (1) PT901466E (cg-RX-API-DMAC10.html)
SK (1) SK282863B6 (cg-RX-API-DMAC10.html)
WO (1) WO1997044315A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA974223B (cg-RX-API-DMAC10.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2193691A1 (en) * 1994-06-22 1995-12-28 Andrew Miller Metalloproteinase inhibitors
US6124333A (en) * 1995-06-22 2000-09-26 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
CA2263886A1 (en) * 1996-12-09 1998-06-18 Warner-Lambert Company Method for treating and preventing heart failure and ventricular dilatation
US6340709B1 (en) 1996-12-17 2002-01-22 Warner-Lambert Company Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
SI0946166T1 (en) * 1996-12-17 2004-06-30 Warner-Lambert Company Llc Use of matrix metalloproteinase inhibitors for promoting wound healing
GB9706255D0 (en) 1997-03-26 1997-05-14 Smithkline Beecham Plc Novel compounds
DE19719621A1 (de) * 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren
AU737218B2 (en) * 1997-07-22 2001-08-09 Shionogi & Co., Ltd. Composition for treating or preventing glomerulopathy
KR20010033473A (ko) * 1997-12-23 2001-04-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Ace 저해제-mmp 저해제의 병용 제제
US6410580B1 (en) 1998-02-04 2002-06-25 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
EP1053226A1 (en) * 1998-02-04 2000-11-22 Novartis AG Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
KR20010041916A (ko) * 1998-03-17 2001-05-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 스타틴-매트릭스 메탈로프로테이나제 저해제 복합제제
EP0967201A1 (en) * 1998-05-20 1999-12-29 Roche Diagnostics GmbH Pharmaceutical agents containing sulfonamids as matrix metalloproteinase inhibitors
CA2337828C (en) * 1998-07-16 2010-08-17 Aventis Pharma Deutschland Gmbh Phosphinic and phosphonic acid derivatives used as pharmaceuticals
CZ2001126A3 (cs) * 1998-07-21 2002-01-16 Warner-Lambert Company Společné účinky ACAT a MMP inhibitorů při léčbě aterosklerotických lézí
DE19851184A1 (de) * 1998-11-06 2000-05-11 Aventis Pharma Gmbh N-Arylsulfonyl-aminosäure-omega-amide
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
KR20010113820A (ko) * 1999-04-19 2001-12-28 시오노 요시히코 옥사디아졸 고리를 갖는 술폰아미드 유도체
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
DK1249233T3 (da) 1999-11-26 2008-11-17 Shionogi & Co NPYY5-antagonister
WO2002028844A1 (en) * 2000-09-29 2002-04-11 Shionogi & Co., Ltd. Thiazole or oxazole derivatives
GB0103303D0 (en) 2001-02-09 2001-03-28 Novartis Ag Organic compounds
MXPA01013326A (es) 2001-02-14 2002-08-26 Warner Lambert Co Bifenil sulfonamidas utiles como inhibisdores de metaloproteinasa de matriz.
WO2003035610A1 (en) * 2001-10-26 2003-05-01 Shionogi & Co., Ltd. Sulfonamide derivative having mmp inhibitory activity
GB0314488D0 (en) * 2003-06-20 2003-07-23 Glaxo Group Ltd Therapeutically useful compounds
JP2007525406A (ja) 2003-12-04 2007-09-06 ワイス ビアリールスルホンアミドおよびその使用方法
ATE449760T1 (de) * 2004-03-22 2009-12-15 Southern Res Inst Nichtpeptidinhibitoren von matrixmetalloproteinasen
CN101279956B (zh) * 2008-04-25 2011-06-15 南昌大学 一种基质金属蛋白酶抑制剂及合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
CA2193691A1 (en) * 1994-06-22 1995-12-28 Andrew Miller Metalloproteinase inhibitors

Also Published As

Publication number Publication date
AU2680397A (en) 1997-12-09
BG102918A (en) 1999-09-30
AU713286B2 (en) 1999-11-25
NO985326L (no) 1999-01-14
PL186416B1 (pl) 2004-01-30
NO312510B1 (no) 2002-05-21
NZ332711A (en) 2000-06-23
HK1019585A1 (en) 2000-02-18
PT901466E (pt) 2002-04-29
WO1997044315A1 (en) 1997-11-27
JP2000511175A (ja) 2000-08-29
ATE207891T1 (de) 2001-11-15
CN1077885C (zh) 2002-01-16
DK0901466T3 (da) 2002-02-18
PL329929A1 (en) 1999-04-26
CZ366898A3 (cs) 1999-02-17
EA199800988A1 (ru) 1999-04-29
BG63940B1 (bg) 2003-07-31
NO985326D0 (no) 1998-11-16
EP0901466A1 (en) 1999-03-17
EA001561B1 (ru) 2001-04-23
DE69707865T2 (de) 2002-05-02
ES2167733T3 (es) 2002-05-16
CN1219166A (zh) 1999-06-09
EE03965B1 (et) 2003-02-17
IL126832A0 (en) 1999-08-17
BR9710841A (pt) 1999-08-17
CZ294063B6 (cs) 2004-09-15
EE9800397A (et) 1999-06-15
SK282863B6 (sk) 2002-12-03
DE69707865D1 (de) 2001-12-06
ZA974223B (en) 1997-12-10
SK157798A3 (en) 1999-04-13
EP0901466B1 (en) 2001-10-31
KR20000011095A (ko) 2000-02-25

Similar Documents

Publication Publication Date Title
EP0901466B1 (en) Biphenylsulfonamide matrix metalloproteinase inhibitors
US5756545A (en) Biphenysulfonamide matrix metal alloproteinase inhibitors
EP0934267B1 (en) Alpha-amino sulfonyl hydroxamic acids as matrix metalloproteinase inhibitors
JP5450105B2 (ja) ビフェニル−4−イル−スルホン酸アリールアミド及びその治療剤としての使用
KR19980086847A (ko) 설포닐아미노카복실산
EP0214639A2 (en) Hydroxamic acid based collagenase inhibitors
JPH10509719A (ja) マトリックスメタロプロテアーゼ阻害因子
KR20000070233A (ko) Mmp 억제제로서 비스-술폰아미드 히드록삼산
ES2277424T3 (es) Derivados de n- hidroxiformamida.
CS271469B2 (en) Method of phenoxyalkylcarboxyl acid's derivatives production
CN101568521A (zh) 硫代芳基取代的锌蛋白酶抑制剂和它们的用途
EP0923569B1 (en) Butyric acid matrix metalloproteinase inhibitors
AU713286C (en) Biphenylsulfonamide matrix metalloproteinase inhibitors
EP0341081A2 (en) Novel amino acid derivatives
CA2133115A1 (en) Carboxylate derivatives exhibiting phospholipase a2 inhibitory activity
MXPA98009083A (en) Metaloproteinase inhibitors with bifenilsulfonam matrix
JP2000508639A (ja) Mmpおよびtnf抑制活性を有するペプチジル化合物
PT99572A (pt) Processo para a preparacao de novas sulfonamidas e de composicoes farmaceuticas que as contem
EP0375557A1 (en) Glycine derivative process for preparation thereof, and pharmaceutical composition containing it
HK1019585B (en) Biphenylsulfonamide matrix metalloproteinase inhibitors

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued